Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProTrans in Type 1 Diabetes
NCT03406585Phase 2Completed
- Sponsor
- NextCell Pharma AB
- Start
- Nov 2017
- Primary completion
- Jul 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing ProTrans with Placebo (2 arms). Primary endpoints: Safety parameters at Day 372 and Preservation of endogenous insulin production at Day 372. Started Nov 2017; status: completed.
02
Drugs
ProTrans
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03406585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406585.